Healthcare SA Technical Prep
Greetings all, I have applied to a few HC focused Investment Banks for Summer Analyst opportunities and I was wondering if anyone had a good resource for preparing for the technical portions? Is there a guide out there that focuses on HC focused techs????
if you google "m&i healthcare guide", it provides a great high level overview of the healthcare industry. it may not be technical heavy but i've found it's an excellent place to start.
SA here at a healthcare group. It really is important to show interest in hc. Its important to follow transactions and understand whats the industry like at a general pov. I would look up public companies that are under each of the main verticals (hc services/providers, medtech, biotech/pharma, life science tools, and healthcare IT) and find initiating coverage reports and learn the industry that way.
There isn't really too much in terms of technicals specific to hc besides biotech modeling.
Just converted a HC SA. I’d imagine being able to speak about the verticals (Life Sciences, Health Services and MedTech), recent big deals and some of the underlying science and a good answer for why healthcare would be a good start.
From what I understand, the only part of HC valuation that is different from basic valuation techniques is Biotech and BioPharma where you need to find your addressable populations, relevant subpopulations and apply a Probability of Success. You should probably know about how clinical trials work, how the FDA approves a drug etc. Be able to understand why DCF would be preferred to comps (obvious cause most don’t have revenues/EBITDA etc) and why an lbo is non sensical here
For news, fierce biotech and fiercebiopharma are good general websites.
Wait holy fuck, did I actually learn something over summer??
If you don't have revenues, why would a DCF be preferred because my thought process is that then you won't have FCF to base it off when you do a DCF. Wouldn't comps make more sense so that you look at other comparables with no revenue etc??
Thought I'd comment on this even though it's super late.
Comps are very hard for biotech. Many dont even have a P/E because no revenues are coming in, thus also making it hard to do P/Sales or EV/Sales
Instead, it's not unheard of to do a 20 year DCF for biotechs. That should give enough runway for the drug(s) to see FDA approval and you can project revenue up to peak, and drop it from there after the patent has expired or you suspect competitors will enter the market.
Remember, the valuation model isn't the end all be all. It reflects your assumptions for the company or drugs. Numbers can vary widely depending how much you risk adjust the drugs probability of success.
Take a look at EvaluatePharma's 2024 view for a big view of critical factors impacting HC. Also Lazard London publishes something useful every year. Take a look at that.
Also google "peak sales" and take a look at how to value companies that don't have revenues.
Also take a look at the more quirky deals and partnerships. Oncology is also a hot space.
Which HC focused banks did you apply to? I’m super interested in the space and want to apply to some HC focused banks.
Illum vitae expedita enim qui ad. Enim quia reiciendis molestiae quaerat qui molestiae quasi cupiditate. Est odio quisquam quod accusamus eveniet inventore. Molestiae temporibus facilis est nostrum. Maxime nostrum sed non. Voluptas repellat illum aliquam omnis dolor.
Sunt et consequatur dolor autem consequatur. Aut iure magni porro ratione aut consectetur suscipit dolorum. Mollitia pariatur ea quis vel quasi.
Nihil qui minus totam. Pariatur sapiente non eos pariatur veniam sit nam hic. Molestiae deleniti porro error quod.
Laudantium cupiditate commodi quia. Dignissimos magnam corrupti quisquam ipsa. Tenetur et quam nostrum laboriosam.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...